CCT241736

CCT241736
Item number Size Datasheet Manual SDS Delivery time Quantity Price
TGM-T4428-5mg 5 mg -

7 - 10 business days*

54.00€
TGM-T4428-1mL 1 ml -

7 - 10 business days*

60.00€
TGM-T4428-10mg 10 mg -

7 - 10 business days*

87.00€
TGM-T4428-25mg 25 mg -

7 - 10 business days*

175.00€
TGM-T4428-50mg 50 mg -

7 - 10 business days*

339.00€
TGM-T4428-100mg 100 mg -

7 - 10 business days*

508.00€
 
Description: CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also... more
Product information "CCT241736"
Description: CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3, CCT241736, an advanced analog of CCT137690, is a preclinical development candidate for the treatment of human malignancies, and in particular AML in adults and children. Target: FLT, Aurora Kinase. Smiles: Cc1nn(C)cc1-c1nc2c(N3CCN(Cc4ccc(Cl)cc4)CC3)c(Cl)cnc2[nH]1. References: Bavetsias V,etal. Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.J Med Chem. 2012 Oct 25,55(20):8721-34.
Supplier: TargetMol
Supplier-Nr: T4428

Properties

Application: FLT3 inhibitor, Aurora kinase inhibitor
MW: 456.37 D
Formula: C22H23Cl2N7

Database Information

CAS : 1402709-93-6| Matching products
KEGG ID : K05092 | Matching products

Handling & Safety

Storage: +4°C
Shipping: +4°C (International: +4°C)
Caution
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow. more
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "CCT241736"
Write a review
or to review a product.
Viewed